文献速递瓣膜外科

Buckberg与Del Nido心脏停搏液在孤立性主动脉瓣置换术中的前瞻性随机对照试验

Buckberg versus Del Nido in isolated aortic valve replacement: a prospective, two-centre, randomized trial.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

这项前瞻性、两中心随机试验于2019年7月至2023年8月纳入311例首次孤立性主动脉瓣置换术成人患者,随机接受Buckberg液(n=159)或Del Nido液(n=152)。主要终点为术后肌酸激酶和超敏肌钙蛋白T峰值水平,两组间无差异;Del Nido组自动恢复心律比例更高、需除颤的室颤更少、术中血糖控制和胰岛素使用更优。

要点

  • 两组术后肌酸激酶和超敏肌钙蛋白T峰值无显著差异。
  • Del Nido组自动恢复心律比例更高(66.7% vs 43.1%)。
  • Del Nido组术中血糖峰值和胰岛素使用更低。

核心结论

  • Del Nido与Buckberg心脏停搏液在孤立性主动脉瓣置换术中未见心肌损伤标志物峰值差异。
  • Del Nido组术中血糖控制更优、自动恢复心律更高、需除颤的室颤更少。

研究设计与样本

  • 前瞻性、两中心、随机试验,2019年7月至2023年8月开展。
  • 纳入首次孤立性主动脉瓣置换术成人患者,随机接受Buckberg液(n=159)或Del Nido液(n=152),共311例。

主要发现

  • 总心脏停搏液用量Del Nido组更高(1000 ml vs 374.5 ml,P < 0.001)。
  • 术后肌酸激酶峰值Buckberg组422 U/L、Del Nido组407 U/L,肌钙蛋白T峰值分别为282 ng/L和258 ng/L,术后第1-5天均无差异。
  • 主动脉阻断钳开放后Del Nido组自动恢复心律比例更高(66.7% vs 43.1%,P < 0.001),需除颤的室颤更少(23.6% vs 49.7%,P < 0.001)。
  • 术中血糖峰值Del Nido组更低(128 mg/dl vs 198 mg/dl,P < 0.001),胰岛素使用比例更低(18.1% vs 51.0%,P < 0.001)。

临床怎么用

  • Del Nido液可作为孤立性主动脉瓣置换术的停搏液选择,有利于术中血糖管理和减少除颤需求。
  • Del Nido液因减少重复给药中断而提供更顺畅的手术流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Interest in Del Nido solution is increasing in adult cardiac surgery. This study compared Del Nido with Buckberg cardioplegia in patients undergoing isolated aortic valve replacement. METHODS: A prospective, two-centre, randomized trial was conducted from July 2019 to August 2023, with adult patients undergoing first-time isolated aortic valve replacement, and were randomized to receive Buckberg (n = 159) or Del Nido (n = 152) solution. Primary end-point was Creatine Kinase and ultrasensitive Troponin T postoperative peak level. RESULTS: A total of 311 patients were recruited. Total cardioplegia volume was higher in Del Nido group (1000 ml vs 374.5 ml, P < 0.001). No differences were observed in peak Creatine Kinase or Troponin T levels (422 vs 407 U/L and 282 vs 258 ng/L for Buckberg and Del Nido, respectively) or during postoperative days 1-5. After cross-clamp removal, patients in Del Nido group showed higher rates of spontaneous rhythm (66.7% vs 43.1%, P < 0.001) and less ventricular fibrillation requiring defibrillation (23.6% vs 49.7%, P < 0.001). Peak intraoperative glucose levels (128 mg/dl vs 198 mg/dl, P < 0.001) and insulin administration (18.1% vs 51.0%, P < 0.001) were lower in the Del Nido group. No other differences were found. CONCLUSIONS: No differences between Del Nido and Buckberg solutions were detected. Del Nido presents better intraoperative glycaemic control, higher spontaneous rhythm, less ventricular fibrillation requiring defibrillation after cross-clamp removal, and more comfortable surgical workflow due to less re-dose interruptions. CLINICAL REGISTRATION NUMBER: EU-CTR number: 2018-002701-59.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tauron-Ferrer M, Roselló-Díez E, Muñoz-Guijosa C, et al. Buckberg versus Del Nido in isolated aortic valve replacement: a prospective, two-centre, randomized trial. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40065513. doi:10.1093/icvts/ivaf054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。